I Barco1, A García-Fernández2, C Chabrera3, M Fraile4, E Vallejo1, J M Lain5, J Deu1, S González6, C González7, E Veloso8, J Torres9, M Torras1, L Cirera6, A Pessarrodona1, N Giménez10,11, M García-Font12. 1. Breast Unit, Department of Gynecology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, C/ Sant Antoni, 21, 08221, Terrassa, Spain. 2. Breast Unit, Department of Gynecology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, C/ Sant Antoni, 21, 08221, Terrassa, Spain. agarcia@mutuaterrassa.es. 3. Department of Nursing, School of Health Science, TecnoCampus Mataró-Maresme, Mataró, Spain. 4. Nuclear Medicine Department, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain. 5. Breast Unit, Department of Gynecology, Hospital of Terrassa, Health Consortium of Terrassa, Terrassa, Spain. 6. Breast Unit, Department of Hemato-oncology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain. 7. Breast Unit, Department of Pathology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain. 8. Breast Unit, Department of Surgery, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain. 9. Breast Unit, Department of Radiology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain. 10. University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain. 11. Laboratory of Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain. 12. University International of Catalunya, Barcelona, Spain.
Abstract
INTRODUCTION: Until recently, completion ALND has been considered the standard of care after a positive SN in breast cancer patients. However, most patients will not display further axillary involvement. The Tenon score is a simple nomogram that can be used intraoperatively to avoid completion ALND in low-risk patients. We aimed at validating the Tenon score on a SN-positive patient sample that had been preoperatively selected using axillary US examination. PATIENTS AND METHOD: We used a retrospective analysis of our bicentric database that included 246 breast cancer patients with a positive SN. We calculated sensitivity, specificity, as well as positive and negative predictive values for each cut-off point. ROCs were constructed and corresponding AUC values were calculated as a measure of discriminative capacity. RESULTS: At least one non-SN was positive in 52 patients (21.1 %). 118 patients (48 %) had a score up to 5. Among them, three had at least one positive non-SN. NPV was 97.5 %. Using that threshold, the ROCs analysis showed an AUC of 0.822 (95 % CI 0.764-0.880). CONCLUSION: Use of preoperative axillary US examination led to a modification of the proposed Tenon cut-off value from 3.5 to 5 to attain good predictive power for non-SN status. Straightforward intraoperative use of the Tenon score may be considered an advantage over other available nomograms.
INTRODUCTION: Until recently, completion ALND has been considered the standard of care after a positive SN in breast cancerpatients. However, most patients will not display further axillary involvement. The Tenon score is a simple nomogram that can be used intraoperatively to avoid completion ALND in low-risk patients. We aimed at validating the Tenon score on a SN-positive patient sample that had been preoperatively selected using axillary US examination. PATIENTS AND METHOD: We used a retrospective analysis of our bicentric database that included 246 breast cancerpatients with a positive SN. We calculated sensitivity, specificity, as well as positive and negative predictive values for each cut-off point. ROCs were constructed and corresponding AUC values were calculated as a measure of discriminative capacity. RESULTS: At least one non-SN was positive in 52 patients (21.1 %). 118 patients (48 %) had a score up to 5. Among them, three had at least one positive non-SN. NPV was 97.5 %. Using that threshold, the ROCs analysis showed an AUC of 0.822 (95 % CI 0.764-0.880). CONCLUSION: Use of preoperative axillary US examination led to a modification of the proposed Tenon cut-off value from 3.5 to 5 to attain good predictive power for non-SN status. Straightforward intraoperative use of the Tenon score may be considered an advantage over other available nomograms.
Authors: Liling Zhu; Liang Jin; Shunrong Li; Kai Chen; Weijuan Jia; Quanyuan Shan; Stephen Walter; Erwei Song; Fengxi Su Journal: Breast Cancer Res Treat Date: 2013-01-05 Impact factor: 4.872
Authors: Amy C Degnim; Carol Reynolds; Gouri Pantvaidya; Shaheen Zakaria; Tanya Hoskin; Sunni Barnes; Margaret V Roberts; Peter C Lucas; Kevin Oh; Meryem Koker; Michael S Sabel; Lisa A Newman Journal: Am J Surg Date: 2005-10 Impact factor: 2.565
Authors: Charles Coutant; Roman Rouzier; Eric Fondrinier; Frederic Marchal; François Guillemin; Nathalie Seince; Anabella Rodrigues; Emile Darai; Serge Uzan; Emmanuel Barranger Journal: Breast Cancer Res Treat Date: 2008-03-14 Impact factor: 4.872
Authors: Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano Journal: J Clin Oncol Date: 2007-05-07 Impact factor: 44.544
Authors: Antonio García Fernández; Carol Chabrera; Marc García Font; Manel Fraile; Sonia Gónzalez; Israel Barco; Clarisa González; Lluís Cirera; Enrique Veloso; José María Lain; Antoni Pessarrodona; Nuria Giménez Journal: Tumour Biol Date: 2013-04-19
Authors: I Barco; M García Font; A García-Fernández; N Giménez; M Fraile; J M Lain; E Vallejo; S González; L Canales; J Deu; M C Vidal; M Rodríguez-Carballeira; A Pessarrodona; C Chabrera Journal: Clin Transl Oncol Date: 2017-08-14 Impact factor: 3.405